To further exploit potential therapeutic options for patients with IKZF1 N159S mutation, 10058‐F4, an appealing inhibitor of MYC was applied in our research, which was reported to exert remarkable anti‐cancer capability in hepatocellular carcinoma,39 prostate cancer40 as well as various haematologic malignancies.41, 42. The gene discussed is MYC; the disease is hepatocellular carcinoma.